Cognitive deficits are a core feature of schizophrenia, account for much of the impaired
functioning associated with the disorder and are not responsive to existing treatments. In this …

Abstract Treatment resistance affects 20–60% of patients with psychiatric disorders; and is
associated with increased healthcare burden and costs up to ten-fold higher relative to …

Glutamate and dopamine systems play distinct roles in terms of neuronal signalling, yet both
have been proposed to contribute significantly to the pathophysiology of schizophrenia. In …

Economics and mental health are intertwined. Apart from the accumulating evidence of the
huge economic impacts of mental ill‐health, and the growing recognition of the effects that …

Objective: Research in both animals and humans indicates that cannabidiol (CBD) has
antipsychotic properties. The authors assessed the safety and effectiveness of CBD in …

Objective: Research and clinical translation in schizophrenia is limited by inconsistent
definitions of treatment resistance and response. To address this issue, the authors …

Abstract Treatment-resistant schizophrenia (TRS), the persistence of positive symptoms
despite≥ 2 trials of adequate dose and duration of antipsychotic medication with …

Abstract Treatment-resistant schizophrenia (TRS) will affect about one in three patients with
schizophrenia. Clozapine is the only treatment approved for TRS, and patients should be …

Abstract Background The glutamate (Glu) and gamma aminobutyric acid (GABA)
hypotheses of schizophrenia were proposed in the 1980s. However, current findings on …

The stagnation in drug development for schizophrenia highlights the need for better
translation between basic and clinical research. Understanding the neurobiology of …